Q3 Earnings Estimate for VolitionRX Issued By Zacks Research

VolitionRX Limited (NYSEAMERICAN:VNRX) – Analysts at Zacks Research raised their Q3 2026 earnings per share (EPS) estimates for VolitionRX in a research report issued to clients and investors on Wednesday, September 16th. Zacks Research analyst S. Ralston now forecasts that the medical research company will post earnings per share of ($0.35) for the quarter, up from their previous forecast of ($0.42). The consensus estimate for VolitionRX’s current full-year earnings is ($1.88) per share. Zacks Research also issued estimates for VolitionRX’s Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($1.55) EPS.

VolitionRX (NYSEAMERICAN:VNRX) last released its quarterly earnings data on Thursday, August 13th. The medical research company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.41 million.

Several other analysts also recently weighed in on VNRX. Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a research note on Monday, August 17th. Maxim Group reissued a “buy” rating and issued a $4.00 price target on shares of VolitionRX in a research note on Thursday, June 18th. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $28.00.

VolitionRX Stock Up 1.9%

Shares of NYSEAMERICAN:VNRX opened at $0.26 on Monday. The company’s 50-day moving average price is $0.62 and its 200 day moving average price is $1.93. The company has a market cap of $3.62 million, a PE ratio of -0.07 and a beta of 1.10. VolitionRX has a fifty-two week low of $0.24 and a fifty-two week high of $14.80.

VolitionRX Company Profile

VolitionRx Limited is a life sciences company developing blood-based diagnostic tests for cancer and other diseases. The company’s technology is based on nucleosomes, fragments of DNA and associated proteins released into the bloodstream during cell death, which may provide information useful for disease detection, monitoring and treatment decisions.

VolitionRx’s product development activities include its Nu.Q technology platform and Nu.Q Vet, a suite of veterinary cancer screening and monitoring tests designed for use in dogs and other companion animals.